 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- || avizakimab (BOS161721) / Boston Pharma
Clinical, P1 data, PK/PD data, Journal, IO biomarker: A double-blind, phase 1, single ascending dose study to assess the safety, pharmacokinetics and pharmacodynamics of BOS161721 in healthy subjects. (Pubmed Central) - Jun 16, 2021
BOS161721 was well tolerated across doses, suppressed IL-21-induced pSTAT3 dose-dependently, and reversed downregulation of genes critical to tolerance induction and T-cell exhaustion induced by IL-21. Further clinical studies are ongoing in patients with systemic lupus erythematosus, in which IL-21 has a pathogenetic role.
- ||| avizakimab (BOS161721) / Boston Pharma
Trial completion: Study of BOS161721 in Systemic Lupus Erythematosus (SLE) Patients on a Background of Limited Standard of Care (clinicaltrials.gov) - Nov 25, 2020
P1b/2, N=143, Completed, Sponsor: Boston Pharmaceuticals
Further clinical studies are ongoing in patients with systemic lupus erythematosus, in which IL-21 has a pathogenetic role. Active, not recruiting --> Completed
- || avizakimab (BOS161721) / Boston Pharma
Trial primary completion date: Study of BOS161721 in Systemic Lupus Erythematosus (SLE) Patients on a Background of Limited Standard of Care (clinicaltrials.gov) - Aug 29, 2020
P1b/2, N=143, Active, not recruiting, Sponsor: Boston Pharmaceuticals
Active, not recruiting --> Completed Trial primary completion date: Aug 2020 --> Nov 2020
- || avizakimab (BOS161721) / Boston Pharma
Enrollment closed: Study of BOS161721 in Systemic Lupus Erythematosus (SLE) Patients on a Background of Limited Standard of Care (clinicaltrials.gov) - Apr 17, 2020
P1b/2, N=186, Active, not recruiting, Sponsor: Boston Pharmaceuticals
Trial primary completion date: Aug 2020 --> Nov 2020 Recruiting --> Active, not recruiting
- ||| avizakimab (BOS161721) / Boston Pharma
Trial completion, Trial primary completion date: Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of BOS161721 in Healthy Subjects (clinicaltrials.gov) - May 1, 2018
P1, N=61, Completed, Sponsor: Boston Pharmaceuticals
Recruiting --> Active, not recruiting Active, not recruiting --> Completed | Trial primary completion date: Aug 2017 --> Apr 2018
- ||| avizakimab (BOS161721) / Boston Pharma
Trial initiation date: Study of BOS161721 in Systemic Lupus Erythematosus (SLE) Patients on a Background of Limited Standard of Care (clinicaltrials.gov) - Mar 3, 2018
P1b/2, N=186, Recruiting, Sponsor: Boston Pharmaceuticals
Active, not recruiting --> Completed | Trial primary completion date: Aug 2017 --> Apr 2018 Initiation date: Dec 2017 --> Feb 2018
- || avizakimab (BOS161721) / Boston Pharma
Enrollment closed: Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of BOS161721 in Healthy Subjects (clinicaltrials.gov) - Feb 7, 2018
P1, N=61, Active, not recruiting, Sponsor: Boston Pharmaceuticals
Initiation date: Dec 2017 --> Feb 2018 Recruiting --> Active, not recruiting
- || avizakimab (BOS161721) / Boston Pharma
Trial primary completion date: Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of BOS161721 in Healthy Subjects (clinicaltrials.gov) - Oct 12, 2017
P1, N=61, Recruiting, Sponsor: Boston Pharmaceuticals
Recruiting --> Active, not recruiting Trial primary completion date: Apr 2017 --> Aug 2017
- avizakimab (BOS161721) / Boston Pharma
New P1 trial: Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of BOS161721 in Healthy Subjects (clinicaltrials.gov) - Jan 30, 2017
P1, N=61, Recruiting, Sponsor: Boston Pharmaceuticals